Anti-interleukin-2 receptor monoclonal antibody Mikbeta1

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-interleukin-2 receptor monoclonal antibody Mikbeta1
Drug Alias NameMikβ1Anti-CD122 monoclonal antibody Mikβ1Interleukin-2 receptor beta monoclonal antibody Mikβ1HuMikβ1-1
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murine
Mechanisms of ActionInterleukin-2 receptor alpha chain inhibitors
TargetsInterleukin-2 receptor alpha chain
Therapy Area/IndicationsCeliac DiseaseLeukemia, Large Granular LymphocyticLeukemia, Lymphoid +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesF. Hoffmann-La Roche LtdNational Institutes Of Health
China Registration ClassN/A

Develop Information

Active CompaniesNational Institutes Of HealthF. Hoffmann-La Roche Ltd
Inactive CompaniesNational Cancer InstituteNational Institute Of Neurological Disorders And Stroke
Active IndicationsLeukemia, Lymphoid
Inactive IndicationsCeliac DiseaseLeukemia, Large Granular LymphocyticLeukemia +[4] 

Other Information

ATC CodeN/A
Related LinksN/A